[1]
|
T. S. Surawicz, F. Davis, S. Freels, E. R. Laws Jr. and H. R. Menck, “Brain Tumor Survival: Results from the National Cancer Data Base,” Journal of Neuro-Oncology, Vol. 40, No. 2, 1998, pp. 151-160.
doi:10.1023/A:1006091608586
|
[2]
|
K. S. Aboody, A. Brown, N. G. Rainov, et al., “Neural Stem Cells Display Extensive Tropism for Pathology in Adult Brain: Evidence from Intracranial Gliomas,” Proceedings of the National Academy of Sciences, Vol. 97, 2000, pp. 12846-12851. doi:10.1073/pnas.97.23.12846
|
[3]
|
S. Benedetti, B. Pirola, B. Pollo, et al., “Gene Therapy of Experimental Brain Tumors Using Neural Progenitor Cells,” Nature Medicine, Vol. 6, 2000, pp. 447-450.
doi:10.1038/74710
|
[4]
|
M. Ehtesham, P. Kabos, K. L. Black and J. S. Yu, “Use of Neural Stem Cells as Therapeutic Vehicles for the Treatment of Malignant Glioma,” Expert Review of Neurotherapeutics, Vol. 3, No. 6, 2003, pp. 883-895.
doi:10.1586/14737175.3.6.883
|
[5]
|
M. Ehtesham, P. Kabos, M. A. Gutierrez, et al., “Induction of Glioblastoma Apoptosis Using Neural Stem Cell-Mediated Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand,” Cancer Research, Vol. 62, No. 24, 2002, pp. 7170-7174.
|
[6]
|
M. Ehtesham, P. Kabos, A. Kabosova, T. Neuman, K. L. Black and J. S. Yu, “The Use of Interleukin 12-Secreting Neural Stem Cells for the Treatment of Intracranial Glioma,” Cancer Research, Vol. 62, No. 20, 2002, pp. 5657-5663.
|
[7]
|
U. Herrlinger, C. Woiciechowski, M. Sena-Esteves, et al., “Neural Precursor Cells for Delivery of Replication-Conditional HSV-1 Vectors to Intracerebral Gliomas,” Molecular Therapy, Vol. 1, No. 4, 2000, pp. 347-357.
doi:10.1006/mthe.2000.0046
|
[8]
|
K. Y. Mapara, C. B. Stevenson, R. C. Thompson and M. Ehtesham, “Stem Cells as Vehicles for the Treatment of Brain Cancer,” Neurosurgery Clinics of North America, Vol. 18, No. 1, 2007, pp. 71-80.
doi:10.1016/j.nec.2006.10.001
|
[9]
|
M. Ehtesham, X. Yuan, P. Kabos, et al., “Glioma Tropic Neural Stem Cells Consist of Astrocytic Precursors and Their Migratory Capacity Is Mediated by CXCR4,” Neo-plasia, Vol. 6, No. 3, 2004, pp. 287-293.
doi:10.1593/neo.03427
|
[10]
|
F. Lazarini, T. N. Tham, P. Casanova, F. Arenzana-Seisdedos and M. Dubois-Dalcq, “Role of the Alpha-Chemokine Stromal Cell-Derived Factor (SDF-1) in the Developing and Mature Central Nervous System,” Glia, Vol. 42, No. 2, 2003, pp. 139-148.
doi:10.1002/glia.10139
|
[11]
|
K. Reiss, R. Mentlein, J. Sievers and D. Hartmann, “Stromal Cell-Derived Factor 1 Is Secreted by Meningeal Cells and Acts as Chemotactic Factor on Neuronal Stem Cells of the Cerebellar External Granular Layer,” Neuroscience, Vol. 115, No. 1, 2002, pp. 295-305.
doi:10.1016/S0306-4522(02)00307-X
|
[12]
|
S. Barbero, R. Bonavia, A. Bajetto, et al., “Stromal Cell-Derived Factor 1alpha Stimulates Human Glioblastoma Cell Growth through the Activation of Both Extracellular Signal-Regulated Kinases 1/2 and Akt,” Cancer Research, Vol. 63, No. 8, 2003, pp. 1969-1974.
|
[13]
|
M. Ehtesham, J. A. Winston, P. Kabos and R. C. Thompson, “CXCR4 Expression Mediates Glioma Cell Invasiveness,” Oncogene, Vol. 25, No. 19, 2006, pp. 2801-2806. doi:10.1038/sj.onc.1209302
|
[14]
|
S. A. Rempel, S. Dudas, S. Ge and J. A. Gutierrez, “Identification and Localization of the Cytokine SDF1 and Its Receptor, CXC Chemokine Receptor 4, to Regions of Necrosis and Angiogenesis in Human Glioblastoma,” Clinical Cancer Research, Vol. 6, No. 1, 2000, pp. 102-111.
|
[15]
|
P. Rajan and R. D. McKay, “Multiple Routes to Astrocytic Differentiation in the CNS,” Journal of Neuroscience, Vol. 18, No. 10, 1998, pp. 3620-3629.
|
[16]
|
M. C. Nunes, N. S. Roy, H. M. Keyoung, et al., “Identification and Isolation of Multipotential Neural Progenitor Cells from the Subcortical White Matter of the Adult Human Brain,” Nature Medicine, Vol. 9, 2003, pp. 439-447. doi:10.1038/nm837
|
[17]
|
M. Ehtesham, C. B. Stevenson and R. C. Thompson, “Stem Cell Therapies for Malignant Glioma,” Neurosurgical Focus, Vol. 19, No. 3, 2005, p. E5.
doi:10.3171/foc.2005.19.3.6
|